Targeting the lung using siRNA and antisense based oligonucleotides

S A Moschos, K Spinks, A E Williams, Mark A Lindsay

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
Original languageEnglish
Pages (from-to)3620-3627
Number of pages8
JournalCurrent Pharmaceutical Design
Volume14
Issue number34
DOIs
Publication statusPublished - 2008

    Fingerprint

Keywords

  • in-vivo
  • antisense
  • mouse
  • induced pulmonary-fibrosis
  • airways
  • oligonucleotide
  • induced pneumonopathy
  • RNA interference
  • antigen-induced eosinophilia
  • phosphorothioate
  • lung
  • siRNA
  • airway hyperresponsiveness
  • gene-expression
  • vascular endothelium
  • small interfering rna
  • common beta-chain

Cite this